127 related articles for article (PubMed ID: 25640377)
1. Comparative evaluation of the risk of malignancy index scoring systems (1-4) used in differential diagnosis of adnexal masses.
Ozbay PO; Ekinci T; Caltekin MD; Yilmaz HT; Temur M; Yilmaz O; Uysal S; Demirel E; Kelekci S
Asian Pac J Cancer Prev; 2015; 16(1):345-9. PubMed ID: 25640377
[TBL] [Abstract][Full Text] [Related]
2. Should cut-off values of the risk of malignancy index be changed for evaluation of adnexal masses in Asian and Pacific populations?
Yavuzcan A; Caglar M; Ozgu E; Ustun Y; Dilbaz S; Ozdemir I; Yildiz E; Gungor T; Kumru S
Asian Pac J Cancer Prev; 2013; 14(9):5455-9. PubMed ID: 24175841
[TBL] [Abstract][Full Text] [Related]
3. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors.
Terzic M; Dotlic J; Likic I; Brndusic N; Pilic I; Ladjevic N; Maricic S; Arsenovic N; Maricic Z
Taiwan J Obstet Gynecol; 2013 Jun; 52(2):253-7. PubMed ID: 23915860
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the risk malignancy index diagnostic value in patients with adnexal masses.
Terzić M; Dotlić J; Ladjević IL; Atanacković J; Ladjević N
Vojnosanit Pregl; 2011 Jul; 68(7):589-93. PubMed ID: 21899180
[TBL] [Abstract][Full Text] [Related]
5. Addition of parity to the risk of malignancy index score in evaluating adnexal masses.
Yavuzcan A; Çağlar M; Özgü E; Üstün Y; Dilbaz S; Ozdemir I; Güngör T; Kumru S
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):518-22. PubMed ID: 25510694
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
7. The risk of malignancy index in discrimination of adnexal masses.
Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A
Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665
[TBL] [Abstract][Full Text] [Related]
8. Role of a risk of malignancy index in clinical approaches to adnexal masses.
Simsek HS; Tokmak A; Ozgu E; Doganay M; Danisman N; Erkaya S; Gungor T
Asian Pac J Cancer Prev; 2014; 15(18):7793-7. PubMed ID: 25292065
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study: The sequential use of the risk malignancy index and contrast-enhanced ultrasonography in differential diagnosis of adnexal masses.
Qiu L; Yang F; Luo H
Medicine (Baltimore); 2018 Jul; 97(29):e11536. PubMed ID: 30024542
[TBL] [Abstract][Full Text] [Related]
10. Sonographic discrimination between benign and malignant adnexal masses in premenopause.
Radosa MP; Vorwergk J; Fitzgerald J; Kaehler C; Schneider U; Camara O; Runnebaum IB; Schleußner E
Ultraschall Med; 2014 Aug; 35(4):339-44. PubMed ID: 23775448
[TBL] [Abstract][Full Text] [Related]
11. Risk of malignancy index in preoperative evaluation of pelvic masses.
Ashrafgangooei T; Rezaeezadeh M
Asian Pac J Cancer Prev; 2011; 12(7):1727-30. PubMed ID: 22126553
[TBL] [Abstract][Full Text] [Related]
12. External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses.
van den Akker PA; Zusterzeel PL; Aalders AL; Snijders MP; Samlal RA; Vollebergh JH; Kluivers KB; Massuger LF
Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):422-5. PubMed ID: 21824712
[TBL] [Abstract][Full Text] [Related]
13. Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass.
Javdekar R; Maitra N
J Obstet Gynaecol India; 2015 Apr; 65(2):117-21. PubMed ID: 25883443
[TBL] [Abstract][Full Text] [Related]
14. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
Moolthiya W; Yuenyao P
Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
[TBL] [Abstract][Full Text] [Related]
15. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
16. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index.
Enakpene CA; Omigbodun AO; Goecke TW; Odukogbe AT; Beckmann MW
J Obstet Gynaecol Res; 2009 Feb; 35(1):131-8. PubMed ID: 19215560
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of Malignancy Risk Indices for Ovarian Masses in Premenopausal and Postmenopausal Women.
Ertas S; Vural F; Vural F; Tufekci EC; Ertas AC; Kose G; Aka N
Asian Pac J Cancer Prev; 2016; 17(4):2177-83. PubMed ID: 27221915
[TBL] [Abstract][Full Text] [Related]
18. Ovarian fibroma/fibrothecoma: retrospective cohort study shows limited value of risk of malignancy index score.
Numanoglu C; Kuru O; Sakinci M; Akbayır O; Ulker V
Aust N Z J Obstet Gynaecol; 2013 Jun; 53(3):287-92. PubMed ID: 23611791
[TBL] [Abstract][Full Text] [Related]
19. Risk of malignancy index as an evaluation of preoperative pelvic mass.
Bouzari Z; Yazdani S; Shirkhani Kelagar Z; Abbaszadeh N
Caspian J Intern Med; 2011; 2(4):331-5. PubMed ID: 24551441
[TBL] [Abstract][Full Text] [Related]
20. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
Dora SK; Dandapat AB; Pande B; Hota JP
J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
